紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗头颈部肿瘤的临床疗效

Efficacy of paclitaxel liposome plus carboplatin versus paclitaxel plus carboplatin for head and neck neoplasms

目的探讨紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗头颈部肿瘤的临床疗效。方法选取2012年12月至2015年12月间安徽医科大学附属巢湖医院收治的96例头颈部肿瘤患者为研究对象,采用随机数表法分为观察组(采用紫杉醇脂质体联合卡铂)与对照组(采用紫杉醇联合卡铂),每组48例。比较两组患者化疗结束后临床疗效、自然杀伤(NK)细胞活性和不良反应发生情况。结果化疗结束后,观察组患者临床治疗有效率和疾病控制率分别为45.8%和81.3%;对照组患者临床治疗有效率和疾病控制率分别为31.3%和72.9%,两组组间比较,差异均无统计学意义(均P>0.05)。观察组患者NK细胞活性高于对照组患者,差异有统计学意义(P<0.05)。观察组患者Ⅲ级和Ⅳ级不良反应发生率分别为10.4%和2.1%,低于对照组患者的20.8%和10.4%,差异有统计学意义(P<0.05)。结论紫杉醇脂质体相较紫杉醇治疗头颈部肿瘤疗效更好,对NK细胞活性影响更小,不良反应更低。

Objective To compare the efficacy of paclitaxel liposome plus carboplatin versus paclitaxel plus carboplatin in treatment of head and neck cancer. Methods Ninety-six patients with head and neck cancer admitted at Chaohu Hospital Affiliated to Anhui Medical University from December 2012 to December 2015 were selected. Using a random number table,patients were divided into an observation group（paclitaxel liposome plus carboplatin） and a contrl group（paclitaxel plus carboplatin） with 48 patients in each group. Clinical efficacy,natural killer（NK） cell activity and incidence of adverse effects were compared between the two groups. Results At the end of chemotherapy,the efficacy rate and disease control rate was 45. 8% and 81. 3%,respectively for the observation group and 31. 3% and 72. 9%,respectively for the control group（all P〈0. 05）. NK cell activity was significantly higher in the observation group than in the control group（P〈0. 05）. The incidence of grade III and grade IV adverse events was 10. 4% and2. 1%,respectively for the observation group and 20. 8% and 10. 4%,respectively for the control group（P〈0. 05）. Conclusion Compared with conventional paclitaxel,paclitaxel liposome has better efficacy and less adverse events for head and neck cancer with less impact on NK cell activity.